Download
HTML Embed
HTML EMBED
Click to Copy

Latest Episodes

Download
HTML Embed
HTML EMBED
Click to Copy
Make Me Smart with Kai and Molly
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report

The U.S. wants El Chapo to pay nearly $12.7B as part of his sentence

by Andy Uhler Jul 16, 2019
Coming up with the number is one thing. Seizing that cash, experts agree, is another matter entirely.
View of the covers of Mexican newspapers in Mexico City, on February 23, 2014, after Mexican drug trafficker  Joaquín “El Chapo” Guzmán was arrested.
Alfredo Estrella/AFP/Getty Images

A last-minute ruling means TV ads won't list drug prices as planned

by Daniel Merino Jul 9, 2019
Some experts doubt that the rule would have been capable of lowering drug prices.
George Frey/Getty Images
The Uncertain Hour

The opioid epidemic in 5 charts

by Tony Wagner Apr 9, 2019
Putting the numbers in broader context.
Dr. Gurcharan Kanwal lost his medical license after an investigation by the Southwest Virginia Drug Task Force found that he was running a "pill mill," or distributing drugs without a legitimate medical purpose, out of this building in Coeburn, Virginia.
Julia Rendleman for Marketplace

From cringeworthy to scary: a history of anti-drug PSAs

by Peter Balonon-Rosen Mar 26, 2019
We remember anti-drug PSAs for reasons their makers didn't intend.
Illustration by Rose Conlon, images courtesy of Partnership for a Drug-Free America, National Crime Prevention Council and Truth.

FDA approves new Johnson & Johnson drug for depression

by Renata Sago Mar 6, 2019
The Food and Drug Administration has approved the first new kind of drug to treat depression since Prozac hit the scene in the late 1980s. Spravato is a nasal spray from Johnson & Johnson that’s a close cousin of ketamine, an…
Janssen Pharmaceutica

The Sinaloa Cartel sans El Chapo

by Barbara Platts and Danielle Chiriguayo Feb 12, 2019
Is losing the leader of a drug-trafficking organization bad for business?
Mexican drug trafficker Joaquín Guzmán Loera, is escorted by marines as he is presented to the press on Feb. 22, 2014 in Mexico City.
RONALDO SCHEMIDT/AFP/Getty Images

Big Pharma is betting big on cancer drugs

by Nancy Marshall-Genzer Jan 3, 2019
Bristol-Myers Squibb announced Thursday that it’s going to acquire another drugmaker, Celgene. The deal is worth about $74 billion. The combined company will have nine products with sales of more than a billion dollars a year, including some blockbuster cancer…
pxhere

Invest in Marketplace today

Ask not what Marketplace can do for you, but what you can do for Marketplace.

Why some people are worried about drug patent protections in the new NAFTA

by Scott Tong Oct 2, 2018
The trade agreement reached over the weekend between the U.S., Canada and Mexico includes longer intellectual property protection periods for the expensive class of drugs known as biologics.
LARS HAGBERG/AFP/Getty Images

There's a new generic drugmaker in town, and it doesn't need to turn a profit

by Marielle Segarra Sep 6, 2018
Across the country, hospitals and clinics are dealing with a really difficult problem: Sometimes they can’t get their hands on certain life-saving generic drugs. So one group of large hospital systems, including the Mayo Clinic and Intermountain Healthcare, has come…

Generic Viagra floods the market. Here’s how Pfizer is reacting

by Dan Gorenstein Jul 13, 2018
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Christopher Furlong/Getty Images